TP53 and non-small cell lung carcinoma: Lee et al23 did not find that patients with NSCLC and TP53 mutations had a significantly worse survival compared to the wild‐type group, but a subgroup analysis showed that TP53 variants with a high mutation frequency were associated with a significantly worse survival compared with wild type.